212 related articles for article (PubMed ID: 21804067)
21. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.
Wool GD; Cabana VG; Lukens J; Shaw PX; Binder CJ; Witztum JL; Reardon CA; Getz GS
FASEB J; 2011 Jan; 25(1):290-300. PubMed ID: 20876212
[TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
Van Lenten BJ; Wagner AC; Jung CL; Ruchala P; Waring AJ; Lehrer RI; Watson AD; Hama S; Navab M; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Nov; 49(11):2302-11. PubMed ID: 18621920
[TBL] [Abstract][Full Text] [Related]
23. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
Navab M; Anantharamaiah GM; Hama S; Garber DW; Chaddha M; Hough G; Lallone R; Fogelman AM
Circulation; 2002 Jan; 105(3):290-2. PubMed ID: 11804981
[TBL] [Abstract][Full Text] [Related]
24. Potential clinical utility of high-density lipoprotein-mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
[TBL] [Abstract][Full Text] [Related]
25. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
[TBL] [Abstract][Full Text] [Related]
26. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma.
Nandedkar SD; Weihrauch D; Xu H; Shi Y; Feroah T; Hutchins W; Rickaby DA; Duzgunes N; Hillery CA; Konduri KS; Pritchard KA
J Lipid Res; 2011 Mar; 52(3):499-508. PubMed ID: 21131532
[TBL] [Abstract][Full Text] [Related]
27. ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.
Cedó L; García-León A; Baila-Rueda L; Santos D; Grijalva V; Martínez-Cignoni MR; Carbó JM; Metso J; López-Vilaró L; Zorzano A; Valledor AF; Cenarro A; Jauhiainen M; Lerma E; Fogelman AM; Reddy ST; Escolà-Gil JC; Blanco-Vaca F
Sci Rep; 2016 Nov; 6():36387. PubMed ID: 27808249
[TBL] [Abstract][Full Text] [Related]
28. Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice.
Li R; Navab M; Pakbin P; Ning Z; Navab K; Hough G; Morgan TE; Finch CE; Araujo JA; Fogelman AM; Sioutas C; Hsiai T
J Lipid Res; 2013 Jun; 54(6):1608-1615. PubMed ID: 23564731
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice.
Rivas-Urbina A; Rull A; Aldana-Ramos J; Santos D; Puig N; Farre-Cabrerizo N; Benitez S; Perez A; de Gonzalo-Calvo D; Escola-Gil JC; Julve J; Ordoñez-Llanos J; Sanchez-Quesada JL
Biomolecules; 2020 May; 10(6):. PubMed ID: 32485898
[TBL] [Abstract][Full Text] [Related]
31. An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.
Lu SC; Atangan L; Won Kim K; Chen MM; Komorowski R; Chu C; Han J; Hu S; Gu W; Véniant M; Wang M
J Lipid Res; 2012 Apr; 53(4):643-52. PubMed ID: 22287724
[TBL] [Abstract][Full Text] [Related]
32. An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI.
Song X; Fischer P; Chen X; Burton C; Wang J
Int J Biol Sci; 2009 Oct; 5(7):637-46. PubMed ID: 19847320
[TBL] [Abstract][Full Text] [Related]
33. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A.
Sharifov OF; Nayyar G; Ternovoy VV; Palgunachari MN; Garber DW; Anantharamaiah G; Gupta H
Innate Immun; 2014 Nov; 20(8):867-80. PubMed ID: 24323453
[TBL] [Abstract][Full Text] [Related]
34. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
Navab M; Hama-Levy S; Van Lenten BJ; Fonarow GC; Cardinez CJ; Castellani LW; Brennan ML; Lusis AJ; Fogelman AM; La Du BN
J Clin Invest; 1997 Apr; 99(8):2005-19. PubMed ID: 9109446
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation.
Nguyen SD; Javanainen M; Rissanen S; Zhao H; Huusko J; Kivelä AM; Ylä-Herttuala S; Navab M; Fogelman AM; Vattulainen I; Kovanen PT; Öörni K
J Lipid Res; 2015 Jun; 56(6):1206-21. PubMed ID: 25861792
[TBL] [Abstract][Full Text] [Related]
36. D-4F, an apolipoprotein A-I mimetic peptide, protects human umbilical vein endothelial cells from oxidized low-density lipoprotein-induced injury by preventing the downregulation of pigment epithelium-derived factor expression.
Liu J; Yao S; Wang S; Jiao P; Song G; Yu Y; Zhu P; Qin S
J Cardiovasc Pharmacol; 2014 Jun; 63(6):553-61. PubMed ID: 24709637
[TBL] [Abstract][Full Text] [Related]
37. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.
Datta G; Chaddha M; Hama S; Navab M; Fogelman AM; Garber DW; Mishra VK; Epand RM; Epand RF; Lund-Katz S; Phillips MC; Segrest JP; Anantharamaiah GM
J Lipid Res; 2001 Jul; 42(7):1096-104. PubMed ID: 11441137
[TBL] [Abstract][Full Text] [Related]
38. An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.
Chen X; Burton C; Song X; McNamara L; Langella A; Cianetti S; Chang CH; Wang J
Int J Biol Sci; 2009 Jul; 5(5):489-99. PubMed ID: 19680471
[TBL] [Abstract][Full Text] [Related]
39. Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse.
de Silva HV; Más-Oliva J; Taylor JM; Mahley RW
J Lipid Res; 1994 Jul; 35(7):1297-310. PubMed ID: 7964191
[TBL] [Abstract][Full Text] [Related]
40. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.
Buga GM; Frank JS; Mottino GA; Hakhamian A; Narasimha A; Watson AD; Yekta B; Navab M; Reddy ST; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Jan; 49(1):192-205. PubMed ID: 17925450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
